EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Prolonged Disease Stability with Durvalumab and Tremelimumab Rechallenge Following Prior Immune Checkpoint Inhibitors: A Case Report

Waseem Abdelrahim, Ebtesam Al-Najjar, Seif El Beheary, Abdullah Esmail

Oncology Research · 2026 · 1-10

DOI: 10.32604/or.2026.083193 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Oncology Research, 2026. Verfasst von Waseem Abdelrahim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Michael E. DeBakey HS for Health Professions, Houston, TX, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Liver Neoplasms, Antibodies, Monoclonal, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedLiver NeoplasmsAntibodies, MonoclonalCarcinoma, HepatocellularImmune Checkpoint InhibitorsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAgedTreatment Outcome

Stichwörter der Autor:innen

Advanced hepatocellular carcinoma (HCC)Durva/Tremeadrenal glandscase reportrechallenge

Substanzen

tremelimumabAntibodies, Monoclonal, HumanizedAntibodies, MonoclonaldurvalumabImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Michael E. DeBakey HS for Health Professions, Houston, TX, USA.
  • Section of GI Oncology, Houston Methodist Neal Cancer Center, Houston Methodist Hospital, Houston, TX, USA.
  • College of Natural Sciences, University of Houston, Houston, TX, USA.

Zitieren

APA

Abdelrahim, W., Al-Najjar, E., El Beheary, S., & Esmail, A. (2026). Prolonged Disease Stability with Durvalumab and Tremelimumab Rechallenge Following Prior Immune Checkpoint Inhibitors: A Case Report. Oncology Research, 0(0), 1-10. https://doi.org/10.32604/or.2026.083193

Vancouver

Abdelrahim W, Al-Najjar E, El Beheary S, Esmail A. Prolonged Disease Stability with Durvalumab and Tremelimumab Rechallenge Following Prior Immune Checkpoint Inhibitors: A Case Report. Oncology Research. 2026;0(0):1-10. doi:10.32604/or.2026.083193

BibTeX
@article{Abdelrahim2026,
  author = {Abdelrahim, Waseem and Al-Najjar, Ebtesam and El Beheary, Seif and Esmail, Abdullah},
  title = {Prolonged Disease Stability with Durvalumab and Tremelimumab Rechallenge Following Prior Immune Checkpoint Inhibitors: A Case Report},
  journal = {Oncology Research},
  year = {2026},
  volume = {0},
  number = {0},
  pages = {1--10},
  doi = {10.32604/or.2026.083193}
}
Kostenlos starten →